亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會(huì)員登錄|免費(fèi)注冊(cè)|忘記密碼|管理入口 返回主站||保存桌面|手機(jī)瀏覽|聯(lián)系方式|購(gòu)物車
企業(yè)會(huì)員第1年

湖北恒綠源生物化工有限公司  

L-肌肽,谷胱甘肽,硫糖鋁,酚酞,黃酚酞,二羥丙茶堿,氨甲環(huán)酸,止血環(huán)酸,CLT酸

搜索
新聞中心
  • 暫無(wú)新聞
產(chǎn)品分類
  • 暫無(wú)分類
聯(lián)系方式
  • 聯(lián)系人:高婕
  • 電話:027-88188016
  • 郵件:hbhlykj@126.com
  • 傳真:027-88188026
  • QQ:1764683941
站內(nèi)搜索
 
榮譽(yù)資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無(wú)鏈接
氟米松
單價(jià) 面議對(duì)比
詢價(jià) 暫無(wú)
發(fā)貨 湖北武漢市付款后3天內(nèi)
品牌 氟米松
型號(hào) 氟米松
規(guī)格 氟米松
過(guò)期 長(zhǎng)期有效
更新 2015-03-03 09:53
 
詳細(xì)信息
 氟米松氟米松 
中文別名: 福如邁塔松; 雙氟美松; 氟美松  
英文名稱: flumethasone 
英文別名: 6-alpha,9-alpha-difluoro-11-beta,17-alpha,21-trihydroxy-16-alpha-methylpregna-1,4-diene-3,20-dione; 6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; (6alpha,11beta,16alpha)-6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; (6alpha,8xi,11beta,14xi,16alpha)-6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione 
CAS號(hào): 2135-17-3 
EINECS號(hào): 218-370-9 
分子式: C22H28F2O5 
分子量: 410.4515  
InChI: InChI=1/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13?,14?,16+,17+,19+,20+,21+,22+/m1/s1  
分子結(jié)構(gòu):   
密度: 1.36g/cm3  
沸點(diǎn): 569.8°C at 760 mmHg  
閃點(diǎn): 298.4°C  
蒸汽壓: 2.33E-15mmHg at 25°C 
©2025 湖北恒綠源生物化工有限公司 版權(quán)所有   技術(shù)支持:化工網(wǎng)   訪問(wèn)量:7936  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |